Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation

Miki Sato, Shinichi Kako, Kana Matsumoto, Kumi Oshima, Yu Akahoshi, Hirofumi Nakano, Tomotaka Ugai, Ryoko Yamasaki, Hidenori Wada, Yuko Ishihara, Kana Sakamoto, Koji Kawamura, Masahiro Ashizawa, Kiriko Terasako-Saito, Shun Ichi Kimura, Hideki Nakasone, Misato Kikuchi, Aki Tanihara, Rie Yamazaki, Yukie TanakaJunya Kanda, Junji Nishida, Kunihiko Morita, Yoshinobu Kanda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In Japan, intravenous busulfan (ivBu) is usually given four times per day as an infusion at 0.8 mg/kg over 2 h. However, as this requires a midnight administration, a once-daily infusion of ivBu at 3.2 mg/kg over 3 h has been investigated as a more convenient and safer method. In this study, 20 Japanese patients received once-daily ivBu in conditioning regimens before allogeneic hematopoietic stem cell transplantation (HSCT), and blood samples were obtained just before, and 3, 3.5, 5, 7, 10, and 24 h after the initiation of ivBu infusion. The outcomes of HSCT were evaluated prospectively. The median area under the plasma concentration versus time curve (AUC) of Bu was 5272 μmol × min/L (range 3491–6284 μmol × min/L), and was similar to those in previous once-daily ivBu studies and to the estimated daily AUC in previous 4-times-daily ivBu studies. All of the patients but two, who died early due to infection, achieved neutrophil engraftment at a median of 25 days after transplantation. No patient was diagnosed with veno-occlusive disease according to the criteria established by Jones. No regimen-related toxicity was significantly associated with AUC. In conclusion, once-daily administration of ivBu has a stable pharmacokinetic profile, and was safely performed in Japanese patients.

Original languageEnglish
Pages (from-to)497-504
Number of pages8
JournalInternational Journal of Hematology
Volume101
Issue number5
DOIs
Publication statusPublished - 2015 May 1
Externally publishedYes

Fingerprint

Busulfan
Hematopoietic Stem Cell Transplantation
Pharmacokinetics
Area Under Curve
Intravenous Infusions
Intravenous Administration
Japan
Neutrophils
Transplantation
Infection

Keywords

  • Area under the plasma concentration versus time curve
  • Conditioning regimen
  • Hematopoietic stem cell transplantation
  • Once-daily intravenous busulfan
  • Pharmacokinetics

ASJC Scopus subject areas

  • Hematology

Cite this

Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. / Sato, Miki; Kako, Shinichi; Matsumoto, Kana; Oshima, Kumi; Akahoshi, Yu; Nakano, Hirofumi; Ugai, Tomotaka; Yamasaki, Ryoko; Wada, Hidenori; Ishihara, Yuko; Sakamoto, Kana; Kawamura, Koji; Ashizawa, Masahiro; Terasako-Saito, Kiriko; Kimura, Shun Ichi; Nakasone, Hideki; Kikuchi, Misato; Tanihara, Aki; Yamazaki, Rie; Tanaka, Yukie; Kanda, Junya; Nishida, Junji; Morita, Kunihiko; Kanda, Yoshinobu.

In: International Journal of Hematology, Vol. 101, No. 5, 01.05.2015, p. 497-504.

Research output: Contribution to journalArticle

Sato, M, Kako, S, Matsumoto, K, Oshima, K, Akahoshi, Y, Nakano, H, Ugai, T, Yamasaki, R, Wada, H, Ishihara, Y, Sakamoto, K, Kawamura, K, Ashizawa, M, Terasako-Saito, K, Kimura, SI, Nakasone, H, Kikuchi, M, Tanihara, A, Yamazaki, R, Tanaka, Y, Kanda, J, Nishida, J, Morita, K & Kanda, Y 2015, 'Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation', International Journal of Hematology, vol. 101, no. 5, pp. 497-504. https://doi.org/10.1007/s12185-015-1756-6
Sato, Miki ; Kako, Shinichi ; Matsumoto, Kana ; Oshima, Kumi ; Akahoshi, Yu ; Nakano, Hirofumi ; Ugai, Tomotaka ; Yamasaki, Ryoko ; Wada, Hidenori ; Ishihara, Yuko ; Sakamoto, Kana ; Kawamura, Koji ; Ashizawa, Masahiro ; Terasako-Saito, Kiriko ; Kimura, Shun Ichi ; Nakasone, Hideki ; Kikuchi, Misato ; Tanihara, Aki ; Yamazaki, Rie ; Tanaka, Yukie ; Kanda, Junya ; Nishida, Junji ; Morita, Kunihiko ; Kanda, Yoshinobu. / Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. In: International Journal of Hematology. 2015 ; Vol. 101, No. 5. pp. 497-504.
@article{b0192444a4cb4c2b8ab450d641b2d9ca,
title = "Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation",
abstract = "In Japan, intravenous busulfan (ivBu) is usually given four times per day as an infusion at 0.8 mg/kg over 2 h. However, as this requires a midnight administration, a once-daily infusion of ivBu at 3.2 mg/kg over 3 h has been investigated as a more convenient and safer method. In this study, 20 Japanese patients received once-daily ivBu in conditioning regimens before allogeneic hematopoietic stem cell transplantation (HSCT), and blood samples were obtained just before, and 3, 3.5, 5, 7, 10, and 24 h after the initiation of ivBu infusion. The outcomes of HSCT were evaluated prospectively. The median area under the plasma concentration versus time curve (AUC) of Bu was 5272 μmol × min/L (range 3491–6284 μmol × min/L), and was similar to those in previous once-daily ivBu studies and to the estimated daily AUC in previous 4-times-daily ivBu studies. All of the patients but two, who died early due to infection, achieved neutrophil engraftment at a median of 25 days after transplantation. No patient was diagnosed with veno-occlusive disease according to the criteria established by Jones. No regimen-related toxicity was significantly associated with AUC. In conclusion, once-daily administration of ivBu has a stable pharmacokinetic profile, and was safely performed in Japanese patients.",
keywords = "Area under the plasma concentration versus time curve, Conditioning regimen, Hematopoietic stem cell transplantation, Once-daily intravenous busulfan, Pharmacokinetics",
author = "Miki Sato and Shinichi Kako and Kana Matsumoto and Kumi Oshima and Yu Akahoshi and Hirofumi Nakano and Tomotaka Ugai and Ryoko Yamasaki and Hidenori Wada and Yuko Ishihara and Kana Sakamoto and Koji Kawamura and Masahiro Ashizawa and Kiriko Terasako-Saito and Kimura, {Shun Ichi} and Hideki Nakasone and Misato Kikuchi and Aki Tanihara and Rie Yamazaki and Yukie Tanaka and Junya Kanda and Junji Nishida and Kunihiko Morita and Yoshinobu Kanda",
year = "2015",
month = "5",
day = "1",
doi = "10.1007/s12185-015-1756-6",
language = "English",
volume = "101",
pages = "497--504",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation

AU - Sato, Miki

AU - Kako, Shinichi

AU - Matsumoto, Kana

AU - Oshima, Kumi

AU - Akahoshi, Yu

AU - Nakano, Hirofumi

AU - Ugai, Tomotaka

AU - Yamasaki, Ryoko

AU - Wada, Hidenori

AU - Ishihara, Yuko

AU - Sakamoto, Kana

AU - Kawamura, Koji

AU - Ashizawa, Masahiro

AU - Terasako-Saito, Kiriko

AU - Kimura, Shun Ichi

AU - Nakasone, Hideki

AU - Kikuchi, Misato

AU - Tanihara, Aki

AU - Yamazaki, Rie

AU - Tanaka, Yukie

AU - Kanda, Junya

AU - Nishida, Junji

AU - Morita, Kunihiko

AU - Kanda, Yoshinobu

PY - 2015/5/1

Y1 - 2015/5/1

N2 - In Japan, intravenous busulfan (ivBu) is usually given four times per day as an infusion at 0.8 mg/kg over 2 h. However, as this requires a midnight administration, a once-daily infusion of ivBu at 3.2 mg/kg over 3 h has been investigated as a more convenient and safer method. In this study, 20 Japanese patients received once-daily ivBu in conditioning regimens before allogeneic hematopoietic stem cell transplantation (HSCT), and blood samples were obtained just before, and 3, 3.5, 5, 7, 10, and 24 h after the initiation of ivBu infusion. The outcomes of HSCT were evaluated prospectively. The median area under the plasma concentration versus time curve (AUC) of Bu was 5272 μmol × min/L (range 3491–6284 μmol × min/L), and was similar to those in previous once-daily ivBu studies and to the estimated daily AUC in previous 4-times-daily ivBu studies. All of the patients but two, who died early due to infection, achieved neutrophil engraftment at a median of 25 days after transplantation. No patient was diagnosed with veno-occlusive disease according to the criteria established by Jones. No regimen-related toxicity was significantly associated with AUC. In conclusion, once-daily administration of ivBu has a stable pharmacokinetic profile, and was safely performed in Japanese patients.

AB - In Japan, intravenous busulfan (ivBu) is usually given four times per day as an infusion at 0.8 mg/kg over 2 h. However, as this requires a midnight administration, a once-daily infusion of ivBu at 3.2 mg/kg over 3 h has been investigated as a more convenient and safer method. In this study, 20 Japanese patients received once-daily ivBu in conditioning regimens before allogeneic hematopoietic stem cell transplantation (HSCT), and blood samples were obtained just before, and 3, 3.5, 5, 7, 10, and 24 h after the initiation of ivBu infusion. The outcomes of HSCT were evaluated prospectively. The median area under the plasma concentration versus time curve (AUC) of Bu was 5272 μmol × min/L (range 3491–6284 μmol × min/L), and was similar to those in previous once-daily ivBu studies and to the estimated daily AUC in previous 4-times-daily ivBu studies. All of the patients but two, who died early due to infection, achieved neutrophil engraftment at a median of 25 days after transplantation. No patient was diagnosed with veno-occlusive disease according to the criteria established by Jones. No regimen-related toxicity was significantly associated with AUC. In conclusion, once-daily administration of ivBu has a stable pharmacokinetic profile, and was safely performed in Japanese patients.

KW - Area under the plasma concentration versus time curve

KW - Conditioning regimen

KW - Hematopoietic stem cell transplantation

KW - Once-daily intravenous busulfan

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84939953140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939953140&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1756-6

DO - 10.1007/s12185-015-1756-6

M3 - Article

C2 - 25672602

AN - SCOPUS:84939953140

VL - 101

SP - 497

EP - 504

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -